BioRestorative Therapies, Inc.
BRTX
$0.18
-$0.01-6.38%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 19.60K | 11.80K | 303.30K | 25.00K | 43.30K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.60K | 11.80K | 303.30K | 25.00K | 43.30K |
| Cost of Revenue | 1.60K | 10.60K | 8.70K | 2.90K | 3.30K |
| Gross Profit | 18.00K | 1.20K | 294.60K | 22.10K | 40.00K |
| SG&A Expenses | 1.22M | 1.12M | 1.37M | 3.12M | 1.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.84M | 3.72M | 3.61M | 4.83M | 2.73M |
| Operating Income | -3.83M | -3.71M | -3.31M | -4.81M | -2.69M |
| Income Before Tax | -3.21M | -3.04M | -2.66M | -5.34M | -1.64M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.21M | -3.04M | -2.66M | -5.34M | -1.64M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.21M | -3.04M | -2.66M | -5.34M | -1.64M |
| EBIT | -3.83M | -3.71M | -3.31M | -4.81M | -2.69M |
| EBITDA | -3.77M | -3.66M | -3.25M | -4.76M | -2.64M |
| EPS Basic | -0.33 | -0.33 | -0.30 | -0.64 | -0.20 |
| Normalized Basic EPS | -0.21 | -0.21 | -0.19 | -0.40 | 0.01 |
| EPS Diluted | -0.33 | -0.33 | -0.30 | -0.64 | -0.20 |
| Normalized Diluted EPS | -0.21 | -0.21 | -0.19 | -0.40 | 0.01 |
| Average Basic Shares Outstanding | 9.75M | 9.12M | 8.74M | 8.36M | 8.13M |
| Average Diluted Shares Outstanding | 9.75M | 9.12M | 8.74M | 8.36M | 8.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |